•Bausch + Lomb dry eye combo drop advances to phase 3 evaluation•Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy•Connecticut ODs win Medicaid pay parity with ophthalmology•Kodiak enrolls first patients in phase 3 DME study for bispecific therapy•Sumitomo Pharma America doses first patient in RP cell therapy trial•Bausch + Lomb dry eye combo drop advances to phase 3 evaluation•Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy•Connecticut ODs win Medicaid pay parity with ophthalmology•Kodiak enrolls first patients in phase 3 DME study for bispecific therapy•Sumitomo Pharma America doses first patient in RP cell therapy trial
HEADLINES
FEATURED
PDUFA target action date of April 30, 2027, is set for the newly-renamed K-911, a nitric oxide-donating bimatoprost formulation.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
